Exhibitor-Hosted Programs are commercially supported educational sessions held in conjunction with the ACT Annual Meeting. Programs are open to all meeting attendees.
Presented by: Charles River
Enjoy fast and fun poster presentations by students, postdocs, and new investigators who have a chance to win up to $500! The rules of this contest are simple: one PowerPoint slide, and two minutes to deliver a presentation to attendees and a panel of judges. All are invited to attend and support the future stars of toxicology!
Presented by: Covance, Inc.
Regenerative therapies promise to redefine medical treatment. Progenitor cells, engineered tissues and/or bioengineered compatible materials aim to replace human cells, regenerate tissue and restore normal function. The FDA-Center for Biologics Evaluation and Research regulates both cellular and gene therapy products and related devices. This program helps attendees navigate the cell therapy IND gauntlet.
Presented by: IONTOX, LLC
Cholastatic drug-induced liver injury (CDILI) still represents a major reason for drug failure. In this presentation the use of an integrated intestine to liver model that can be used to assess CDILI at target organ relevant doses will be presented. The model includes a human 3D intestinal model linked to a liver compartment consisting of human primary hepatocytes in sandwich culture.
Presented by: Southern Research
Development of in vitro models to screen for teratogenicity is essential for reducing animal use in toxicity testing. Additionally, due to mounting evidence linking endocrine disruption with adverse environmental and human health outcomes, regulatory authorities are focusing on reducing the use of endocrine disrupting chemicals. This session describes the technical aspects of the Chick Embryo Screen for Teratogenicity (ChEST) assay, and assays available to screen for endocrine disruption liability early in the development process.
Presented by: BIAL - Portela & Cª. S.A.
The novel fatty acid amino hydrolase (FAAH) inhibitor BIA 10-2474 is the compound used in the clinical trial BIA-102474-101 (conducted by Biotrial, Rennes, France) in which one person died and four other volunteers had mild-to-severe neurological symptoms. This session will review the toxicology, pharmacology, and clinical pharmacology of BIA 10-2474.
Presented by: MilliporeSigma
The CAN Multiflow. assay is a high-throughput 96-well genetic toxicology screening assay that determines a Clastogenic, Aneugenic or Non-Genotoxic mode of action. This assay measures changes in multiple DNA damage response biomarkers. Samples are processed for flow cytometry and data is analyzed using Machine Learning to yield final prediction.
Presented by: WuXi AppTec, Laboratory Testing Division
During this session, IND-enabling studies and timing, as well as documentation and submission requirements will be reviewed and discussed. Timing is very important during your IND planning and submission. We will discuss all the services needed for an IND, such as toxicology, DMPK, pharmacology, CMC, bioanalytical and analytical services. What comes after the studies are completed will be discussed as well: document preparation and submission. Timelines, filing, having an integrated platform, flexible collaboration, and high quality are all very important when completing your IND submission.
Presented by: Charles River
Immuno-oncology is an innovative cancer therapy which leverages the body’s immune system to fight cancer cells. In support of drug efficacy evaluation in animal models, human and/or mouse immune cell subtypes can be differentiated and quantified using immunohistochemistry and automated image analysis offering superior specificity and sensitivity.
Presented by: Instem
Companies are under enormous pressure to quickly produce high-quality target risk assessments to make drug development decisions. During this session, we will look at current industry trends and how augmented intelligence, coupled with data mining technologies, are enhancing this area.
Presented by: Leadscope, Inc.
This program will describe the development of standardized in silico protocols detailing the prediction of many toxicological endpoints. The protocols will ensure any in silico assessments are performed in a consistent, repeatable, welldocumented and defendable manner. Leadscope has created a 55-member international cross-industry consortium for the development of these protocols
Presented by: Vet Path Services, Inc.
Pathology peer review is an important part of the toxicologic pathology assessment of drugs and chemicals. The basis of pathology raw data, how peer review is normally structured, and current controversies will be discussed. The aim of this presentation is to demystify for toxicologists what happens in a peer review. It provides perspective on how comprehensive peer review should be conducted.